Ditchcarbon
  • Contact
  1. Organizations
  2. Boehringer Ingelheim Corporation
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated a month ago

Boehringer Ingelheim Corporation Sustainability Profile

Company website

Boehringer Ingelheim Corporation, a leading global pharmaceutical company, is headquartered in the United States and operates extensively across Europe, Asia, and other regions. Founded in 1885, the company has established itself as a key player in the pharmaceutical and animal health industries, focusing on innovative research and development. Boehringer Ingelheim is renowned for its core products, which include prescription medications, vaccines, and animal health solutions. Their commitment to advancing healthcare through unique therapeutic approaches sets them apart in a competitive market. With a strong emphasis on human and veterinary medicine, the company has achieved notable milestones, including significant advancements in respiratory and cardiovascular treatments. As a prominent entity in the pharmaceutical landscape, Boehringer Ingelheim continues to enhance its market position through a dedication to innovation and sustainability, making a lasting impact on global health.

DitchCarbon Score

How does Boehringer Ingelheim Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Boehringer Ingelheim Corporation's score of 23 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.

27%

Let us know if this data was useful to you

Boehringer Ingelheim Corporation's reported carbon emissions

Inherited from C.H. Boehringer Sohn AG & Co. KG

Boehringer Ingelheim Corporation, headquartered in the US, currently does not provide specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of C.H. Boehringer Sohn AG & Co. KG, which may influence its climate commitments and performance metrics. Despite the lack of specific emissions data, Boehringer Ingelheim Corporation is part of a broader corporate family that may have established climate initiatives. However, no specific reduction targets or commitments have been documented for the corporation itself. The absence of data on initiatives such as Science Based Targets Initiative (SBTi) or other climate pledges suggests that the company may still be in the process of developing its climate strategy. As a subsidiary, Boehringer Ingelheim Corporation's climate actions may be aligned with those of its parent company, but specific details on emissions reductions or commitments are not available at this time. The company is expected to engage in ongoing efforts to address climate change, reflecting industry standards and practices.

How Carbon Intensive is Boehringer Ingelheim Corporation's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Boehringer Ingelheim Corporation's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Boehringer Ingelheim Corporation's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Boehringer Ingelheim Corporation is in US, which has a low grid carbon intensity relative to other regions.

Boehringer Ingelheim Corporation's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Boehringer Ingelheim Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Boehringer Ingelheim Corporation's Emissions with Industry Peers

OptiNose US, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 16 days ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 17 days ago

Invetx, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 17 days ago

Biogen

US
•
Pharmaceutical Preparation Manufacturing
Updated 17 days ago

Merck Animal Health

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251119.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy